Terms: = Lung cancer AND SDC4, ENSG00000124145, 6385, P31431, SYND4, MGC22217 AND Treatment
15 results:
1. Different effects of crizotinib treatment in two non-small cell lung cancer patients with sdc4::ROS1 fusion variants.
Ohishi Y; Nakanishi Y; Hirotani Y; Suzuki A; Tanino T; Nishimaki-Watanabe H; Kobayashi H; Nozaki F; Ohni S; Tang X; Hayashi K; Nakagawa Y; Shimizu T; Tsujino I; Takahashi N; Gon Y; Masuda S
Thorac Cancer; 2024 Jan; 15(1):89-93. PubMed ID: 38093515
[TBL] [Abstract] [Full Text] [Related]
2. Low expression of ZFP36L1 in osteosarcoma promotes lung metastasis by inhibiting the sdc4-TGF-β signaling feedback loop.
Ma M; Zhuang J; Li H; Mi R; Song Y; Yang W; Lu Y; Shen X; Wu Y; Shen H
Oncogene; 2024 Jan; 43(1):47-60. PubMed ID: 37935976
[TBL] [Abstract] [Full Text] [Related]
3. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract] [Full Text] [Related]
4. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract] [Full Text] [Related]
6. A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies.
Ni M; Liu X; Meng Z; Liu S; Jia S; Liu Y; Zhou W; Wu J; Zhang J; Guo S; Li J; Wang H; Zhang X
BMC Complement Med Ther; 2020 Jun; 20(1):174. PubMed ID: 32503508
[TBL] [Abstract] [Full Text] [Related]
7. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract] [Full Text] [Related]
8. Different Types of
He Y; Sheng W; Hu W; Lin J; Liu J; Yu B; Mao X; Zhang L; Huang J; Wang G
Oncol Res; 2019 Aug; 27(8):901-910. PubMed ID: 30940295
[No Abstract] [Full Text] [Related]
9. Characteristics and Outcome of ROS1-Positive Non-Small Cell lung cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract] [Full Text] [Related]
10. Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.
Zhu YC; Lin XP; Li XF; Wu LX; Chen HF; Wang WX; Xu CW; Shen JF; Wei JG; Du KQ
Thorac Cancer; 2018 Jan; 9(1):159-163. PubMed ID: 28971587
[TBL] [Abstract] [Full Text] [Related]
11. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
[TBL] [Abstract] [Full Text] [Related]
12. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract] [Full Text] [Related]
13. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC
Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003
[TBL] [Abstract] [Full Text] [Related]
14. [Radiofrequency ablation as an alternative treatment for organ confined renal tumor].
Gallego Vilar D; José Povo Martin I; Miralles Aguado J; Garau Perelló C; Bosquet Sanz M; Gimeno Argente V; Cifrián M; García Vila J; Gallego Gómez J
Actas Urol Esp; 2010 Nov; 34(10):860-5. PubMed ID: 21159281
[TBL] [Abstract] [Full Text] [Related]
15. A systematic review of radiofrequency ablation for lung tumors.
Zhu JC; Yan TD; Morris DL
Ann Surg Oncol; 2008 Jun; 15(6):1765-74. PubMed ID: 18368456
[TBL] [Abstract] [Full Text] [Related]
